EMPLOYMENT AGREEMENTEmployment Agreement • February 16th, 2017 • Alexion Pharmaceuticals Inc • Pharmaceutical preparations • Connecticut
Contract Type FiledFebruary 16th, 2017 Company Industry JurisdictionThis EMPLOYMENT AGREEMENT (the “Agreement”) is dated as of December 12, 2016, by and between Alexion Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and David J. Anderson (the “Employee”).
CONFIDENTIAL SEPARATION AGREEMENT AND RELEASEConfidential Separation Agreement and Release • February 16th, 2017 • Alexion Pharmaceuticals Inc • Pharmaceutical preparations • Delaware
Contract Type FiledFebruary 16th, 2017 Company Industry JurisdictionThis Confidential Separation Agreement and Release (“Agreement”), is made effective as of December 11, 2016, by and between Vikas Sinha, his agents, assignees, heirs, executors, administrators, beneficiaries, trustees, legal representatives and assigns ("SINHA"), and Alexion Pharmaceuticals, Inc., its subsidiaries, affiliates, divisions and related entities, and its and their successors, assigns, present or former directors, officers, agents, fiduciaries or employees or any person acting on behalf of any of them (“ALEXION”).
EMPLOYMENT AGREEMENTEmployment Agreement • February 16th, 2017 • Alexion Pharmaceuticals Inc • Pharmaceutical preparations • Connecticut
Contract Type FiledFebruary 16th, 2017 Company Industry JurisdictionThis EMPLOYMENT AGREEMENT (the “Agreement”) dated as of December 12, 2016 by and between Alexion Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and David Brennan (the “Employee”).
CONFIDENTIAL RELEASE AND SEPARATION AGREEMENTConfidential Release and Separation Agreement • February 16th, 2017 • Alexion Pharmaceuticals Inc • Pharmaceutical preparations • Connecticut
Contract Type FiledFebruary 16th, 2017 Company Industry JurisdictionThis Confidential Release and Separation Agreement (“Agreement”), is made effective as of December 11, 2016, by and between DAVID HALLAL, his agents, assignees, heirs, executors, administrators, beneficiaries, trustees, legal representatives and assigns (“HALLAL”), and Alexion Pharmaceuticals, Inc., its subsidiaries, parents, affiliates, divisions and related entities, and its and their successors, predecessors, assigns, present or former directors, officers, executives, agents, attorneys, shareholders, fiduciaries or employees or any person acting on behalf of any of them (“ALEXION”).